These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21883455)

  • 41. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival.
    Welling TH; Fu S; Wan S; Zou W; Marrero JA
    Cancer Invest; 2012 Dec; 30(10):689-97. PubMed ID: 23072563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma.
    Bachtiar I; Santoso JM; Atmanegara B; Gani RA; Hasan I; Lesmana LA; Sulaiman A; Gu J; Tai S
    Clin Chim Acta; 2009 Jan; 399(1-2):97-101. PubMed ID: 18926809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma.
    Ozkan H; Erdal H; Tutkak H; Karaeren Z; Yakut M; Yüksel O; Köklü S
    Digestion; 2011; 83(1-2):83-8. PubMed ID: 21042019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.
    Tangkijvanich P; Tosukhowong P; Bunyongyod P; Lertmaharit S; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 1999 Mar; 30(1):110-4. PubMed ID: 10695798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of staging systems to predict survival in hepatocellular carcinoma.
    Pascual S; Zapater P; Such J; García-Herola A; Sempere L; Irurzun J; Palazón JM; Carnicer F; Pérez-Mateo M
    Liver Int; 2006 Aug; 26(6):673-9. PubMed ID: 16842323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
    Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma.
    Omagari K; Honda S; Kadokawa Y; Isomoto H; Takeshima F; Hayashida K; Mizuta Y; Murata I; Kohno S
    J Gastroenterol Hepatol; 2004 Jul; 19(7):805-11. PubMed ID: 15209629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usefulness of the CLIP scoring system for prediction of postoperative prognosis of patients with large hepatocellular carcinoma.
    Noda T; Sasaki Y; Yamada T; Eguchi H; Yano M; Ohigashi H; Ishikawa O; Imaoka S
    J Hepatobiliary Pancreat Surg; 2009; 16(4):538-45. PubMed ID: 19367360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
    World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein.
    Nouso K; Kobayashi Y; Nakamura S; Kobayashi S; Takayama H; Toshimori J; Kuwaki K; Hagihara H; Onishi H; Miyake Y; Ikeda F; Shiraha H; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K
    J Gastroenterol Hepatol; 2011 Jul; 26(7):1195-200. PubMed ID: 21410750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.
    Hayashi M; Shimizu T; Hirokawa F; Inoue Y; Komeda K; Asakuma M; Miyamoto Y; Takeshita A; Shibayama Y; Tanigawa N
    Am Surg; 2011 May; 77(5):572-8. PubMed ID: 21679590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
    Giannini EG; Sammito G; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Trevisani F;
    Cancer; 2014 Jul; 120(14):2150-7. PubMed ID: 24723129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis.
    Nanashima A; Omagari K; Tobinaga S; Shibata K; Sumida Y; Mine M; Morino S; Shibasaki S; Ide N; Shindou H; Nagayasu T
    Eur J Surg Oncol; 2005 Oct; 31(8):882-90. PubMed ID: 15993031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.